The Cost of Sickness: Why America Spends the Most and Lives the Least

The Numbers That Don’t Add Up

The United States spent approximately $4.5 trillion on healthcare in 2022 — $13,493 per person. The next highest per-capita spender in the OECD is Germany at roughly $7,383. Switzerland is third at $7,179. The U.S. spends nearly double any comparable nation. France, the United Kingdom, Japan, and Australia all provide universal coverage for between $4,000 and $6,500 per person annually.

The outcomes data is unambiguous. The U.S. ranks 32nd globally in life expectancy. It ranks last among 11 high-income countries on healthcare system performance according to the Commonwealth Fund — a ranking that factors in access, equity, administrative efficiency, care quality, and health outcomes. It has done so in every iteration of that report since 2004. The gap is not narrowing.

More precisely: a 2021 JAMA study found that Americans aged 15–49 die from chronic and noncommunicable diseases alone at rates that exceed total mortality in comparable countries. The authors concluded that the United States is not simply spending more for less — it is experiencing a systemic failure in preventing death from conditions that other wealthy nations treat effectively. The study estimated that if the U.S. achieved the same age-standardized mortality rates as comparable nations, approximately 600,000 fewer Americans would die each year.

A 2021 analysis found that for Americans aged 15–49 and 50–69, the United States had more deaths from chronic and noncommunicable diseases alone than many peer countries had from all causes combined. The healthy life expectancy gap exceeded 12 years.

Medical debt is a uniquely American public health phenomenon. A 2022 Kaiser Family Foundation survey found that approximately 100 million Americans carry some form of medical debt. A 2019 study in the American Journal of Public Health found that medical issues contribute to approximately 66.5% of all U.S. personal bankruptcies — a figure with no equivalent in any other high-income country. In Canada, Germany, France, and the U.K., medical expenses rarely appear in bankruptcy proceedings because healthcare costs are predictable and bounded. In the U.S., a single hospitalization can eliminate a family’s net worth.

The Drug Pricing Architecture

The Same Drug. Different Country. Different Price.

Drug pricing in the United States is not regulated. There is no statutory cap, no government negotiation authority beyond limited Medicare IRA provisions, and no requirement that prices bear any relationship to development costs. Identical medications carry prices that vary by 200–400% based solely on geography.

Insulin was discovered in 1921. The inventors sold the patent to the University of Toronto for $1, explicitly so it could be distributed cheaply. Insulin became proprietary when companies made minor molecular modifications to create patentable analogs. Those patents have been extended through “evergreening” for over a century.

Evergreening is a documented industry practice: a manufacturer makes minor modifications to an existing drug — a new coating, a different dosing schedule, an extended-release formulation — and obtains a new 20-year patent, resetting the exclusivity clock. The FDA has approved thousands of such secondary patents. A 2018 study in PLOS Medicine found that among the 12 best-selling drugs in the United States, manufacturers had obtained an average of 38 patents per drug — with some drugs accruing over 100 patents. Humira, the top-selling drug in U.S. history, had a thicket of 257 patents as of 2023, blocking biosimilar competition for years beyond its initial exclusivity.

The Inflation Reduction Act of 2022 gave Medicare the authority to negotiate drug prices for the first time in its 60-year history. The first 10 drugs subject to negotiation were announced in 2023. The pharmaceutical industry had spent more than two decades fighting this authority — lobbying against the Medicare Modernization Act of 2003 specifically included a ban on price negotiation, a provision that stood for nearly two decades. The lobbying cost: the pharmaceutical industry spends more on lobbying than any other sector in the United States, averaging $370 million per year from 2015–2022 per OpenSecrets.

The PBM Mechanism: Three Companies, 80% Control

Pharmacy Benefit Managers are intermediaries between drug manufacturers, insurers, and pharmacies. Three companies control approximately 80% of all U.S. prescription drug distribution.

The structural conflict: PBMs favor high-list-price drugs because rebates are calculated as a percentage of list price. A $500 drug generating a $200 rebate produces more PBM revenue than a $100 generic — even if clinically equivalent. Documented by the FTC in a 2024 interim report.

The FTC’s July 2024 interim report on PBMs was remarkable for its directness. The commission concluded that the three largest PBMs — which had all acquired significant pharmacy and insurance operations — were engaging in practices that raised drug costs for patients and taxpayers while enriching themselves. The report documented that PBMs charge plan sponsors and patients more for drugs than they pay pharmacies, keeping the undisclosed difference as profit. It found that between 2017 and 2022, the six largest PBMs generated approximately $1.4 trillion in combined revenues. The commission voted to expand the investigation into a full rulemaking proceeding.

The vertical integration of the PBM industry has created entities that simultaneously act as insurer (deciding what’s covered), PBM (deciding which drugs are covered at what tier), specialty pharmacy (dispensing the drugs they prefer), and employer benefit consultant (advising companies to use their own PBM). CVS Health owns Aetna, CVS Caremark, and thousands of CVS pharmacies. UnitedHealth Group owns UnitedHealthcare, OptumRx, and Optum Specialty Pharmacy. Each entity in the chain extracts margin at every handoff.

Prior Authorization and the Denial Economy

Prior authorization denials tripled between 2019 and 2023. The AMA documented in a 2023 survey that 93% of physicians reported prior authorization delays to necessary care, and 25% reported it had led directly to a serious adverse event.

Prior authorization was originally designed to prevent unnecessary or experimental procedures. The documented reality in 2024 is that it has become a profit mechanism. Denying a claim costs the insurer nothing administratively and gains them the premium for another year if the patient stays enrolled. The appeal rate is low — insurers know that physicians and patients, exhausted by the process, often abandon claims after the first denial. A 2023 Senate Finance Committee investigation found that some insurers denied large volumes of claims using AI systems without individualized clinical review.

Dr. Timothy Fagan, a former UnitedHealth medical director, filed a whistleblower complaint in 2023 alleging he was instructed to deny claims within two minutes of review — a timeframe he stated was incompatible with clinical judgment. The company denied those allegations. In December 2023, UnitedHealth CEO Brian Thompson was fatally shot outside a hotel in New York City. In the immediate aftermath, the public response on social media revealed the breadth of American consumer rage at insurance denial practices — a response that national media coverage documented extensively as a reflection of lived experience with the prior authorization system.

Hospital Pricing: The Chargemaster

U.S. hospitals maintain a “chargemaster” — a list of prices for every procedure. Chargemaster rates are typically 3–10x actual cost. Uninsured patients are billed at or near chargemaster rates. A 2023 analysis found 75% of hospitals were not compliant with federal price transparency rules, and those that did publish showed price variations of up to 1,800% for identical procedures within the same metro area.

Hospital consolidation has accelerated chargemaster inflation. When a hospital system acquires a competitor, the newly merged entity can negotiate higher rates with insurers by threatening to leave networks. A 2022 RAND study found that hospital prices for the same services were, on average, 224% of Medicare rates for privately insured patients — with some hospitals billing over 800% of Medicare. The markup is highest in markets with the least competition. Congress passed the Hospital Price Transparency Rule in 2019, requiring hospitals to publish their rates. Implementation and enforcement have been incomplete.

For-profit hospital systems reported record profits in 2021 and 2022 — the same years that saw unprecedented federal COVID relief spending flow to hospitals. HCA Healthcare, the largest for-profit hospital chain in the U.S., reported net income of $7 billion in 2021. Many non-profit hospitals — which receive significant tax exemptions in exchange for community benefit obligations — spent less on charity care than the value of their tax exemptions, per an Axios analysis of IRS filings.

Who Designed This System

The U.S. healthcare system’s pricing structure did not emerge organically. It was constructed through specific policy decisions, lobbied for over decades, and maintained through campaign finance. The pharmaceutical industry’s negotiation ban in Medicare was written by a pharmaceutical industry lobbyist, Billy Tauzin, who then left Congress and became president of PhRMA at a salary reportedly over $2 million per year. This is documented in public record and multiple investigative reports.

The insurance industry and hospital systems collectively spend more on federal lobbying than the defense, aerospace, and oil industries. Between 2010 and 2022, healthcare sector entities spent over $10 billion on federal lobbying — more than any other sector — per OpenSecrets. Pharmaceutical companies alone contributed over $400 million to congressional campaigns during that period. The industry employs more registered lobbyists in Washington than there are members of Congress.

The revolving door is documented: FDA commissioners have moved to pharmaceutical company advisory boards. Centers for Medicare and Medicaid Services administrators have joined insurance company executive teams. Congressional staffers who wrote healthcare legislation have become lobbyists for the industries they regulated. This is legal under current U.S. law, subject to cooling-off periods that are routinely structured around.

Medical Debt: The Distinctly American Crisis

Medical debt is, with narrow exceptions, a uniquely American phenomenon among high-income countries. A KFF survey in 2022 found that approximately 100 million Americans — roughly 40% of adults — carry some form of medical debt. Medical bills are the leading cause of personal bankruptcy in the United States, accounting for an estimated 66% of all personal bankruptcies per a 2019 American Journal of Public Health study — a figure that has been contested but not refuted by the hospital or insurance industries.

The mechanics of medical debt generation are well-documented. Hospital chargemasters — the internal master price lists that hospitals use as starting points for negotiations with insurers — list prices that are typically 2-4x what insurers actually pay and 3-10x what Medicare pays for equivalent services. The RAND Corporation documented in 2022 that private insurers pay hospitals an average of 224% of Medicare rates for the same services. Uninsured patients, who have no negotiating leverage, are typically billed at or near chargemaster rates — meaning they pay the highest prices in the system while having the least ability to pay.

Surprise billing — receiving care from an out-of-network provider at an in-network facility without prior notice — was a documented industry practice that generated significant medical debt for insured patients. The No Surprises Act, which took effect January 1, 2022, eliminated most surprise billing in emergency settings. The law has reduced but not eliminated surprise billing in non-emergency contexts.

Medical debt is treated as ordinary consumer debt in the U.S. credit system. As of 2023, the three major credit bureaus announced they would remove most medical debt from credit reports — a significant change, but one implemented by private companies rather than legislation, meaning it can be reversed. The Consumer Financial Protection Bureau proposed rules in 2024 to prohibit medical debt from credit reports entirely.

What the Spending Actually Produces

The Commonwealth Fund's 2021 Mirror Mirror report, which evaluates healthcare system performance across 11 high-income countries, ranked the United States last overall — despite spending nearly twice as much per capita as the next-highest-spending country. The U.S. ranked last on access, equity, healthcare outcomes, and administrative efficiency. It ranked first on care process quality — meaning when Americans do receive care, it is often technically excellent.

The specific outcome gaps are documented and wide. U.S. maternal mortality rates are approximately 3x those of the UK and Canada, and 10x those of Norway — the highest of any high-income nation. Infant mortality rates are above the OECD average. Preventable mortality — deaths from conditions that should not be fatal with timely, effective care — is higher in the U.S. than in any comparable country. These outcomes exist in a country that spends more on healthcare per person than any other nation by a wide margin.

The life expectancy gap that opened between the U.S. and peer nations accelerated during the COVID-19 pandemic and has not fully closed. U.S. life expectancy at birth fell to 76.4 years in 2021, the lowest since 1996 and approximately 5 years below the OECD average. Opioid deaths, gun violence, and the administrative barriers to care documented throughout this article all contribute to a mortality pattern that the $4.5 trillion annual healthcare spend has not addressed.

The Structural Question

The United States is the only high-income country without universal healthcare coverage and the only OECD nation that does not regulate drug prices nationally. An estimated 34% of U.S. healthcare spending goes to billing and administration. In Canada, the equivalent is approximately 12%. The administrative overhead alone — the excess beyond what a single-payer system would require — represents approximately $800 billion per year in spending that produces no clinical outcome.

Single-payer proposals have been introduced in Congress repeatedly. The Medicare for All Act, introduced by Sen. Bernie Sanders, has been analyzed by multiple independent bodies including the Political Economy Research Institute at UMass Amherst, which estimated it would reduce total U.S. healthcare spending by approximately $450 billion annually while covering the uninsured. The Congressional Budget Office has not scored the bill because it requires assumptions about negotiated drug prices and utilization changes the agency considers too uncertain to model. The bill has never received a committee vote.

The system is not failing. It is succeeding at exactly what it was designed to do: generating profit for insurers, PBMs, hospital systems, pharmaceutical companies, and the financial infrastructure that connects them. The political question — why the system remains unchanged despite documented outcomes that rank it last among its peers — is answered by the lobbying and campaign finance record above. The $10 billion spent on federal healthcare lobbying between 2010 and 2022 purchased the status quo. The next article in this series examines the patent architecture that keeps drug prices structurally unreachable.